Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non‐small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of …
T Kato, H Yoshioka, I Okamoto, A Yokoyama… - Cancer …, 2015 - Wiley Online Library
In LUX‐Lung 3, afatinib significantly improved progression‐free survival (PFS) versus
cisplatin/pemetrexed in EGFR mutation‐positive lung adenocarcinoma patients and overall …
cisplatin/pemetrexed in EGFR mutation‐positive lung adenocarcinoma patients and overall …
Pemetrexed had significantly better clinical efficacy in patients with stage IV lung adenocarcinoma with susceptible EGFR mutations receiving platinum-based …
CJ Yang, MJ Tsai, JY Hung, TC Liu… - OncoTargets and …, 2016 - Taylor & Francis
Background Increased evidences show that epidermal growth factor receptor (EGFR)-
tyrosine kinase inhibitors such as gefitinib could prolong progression-free survival (PFS) …
tyrosine kinase inhibitors such as gefitinib could prolong progression-free survival (PFS) …
Clinical outcomes after first-line EGFR inhibitor treatment for patients with NSCLC, EGFR mutation, and poor performance status
Y Okuma, Y Hosomi, M Nagamata… - Anticancer …, 2013 - ar.iiarjournals.org
Background: The phase II NEJ001 trial suggested that gefitinib was active against advanced
non-small cell lung cancer (NSCLC) even in patients with poor performance status (PS) …
non-small cell lung cancer (NSCLC) even in patients with poor performance status (PS) …
Smoking history is more predictive of survival benefit from erlotinib for patients with non-small cell lung cancer (NSCLC) than EGFR expression
GM Clark, D Zborowski, P Santabárbara… - Journal of Clinical …, 2005 - ascopubs.org
7033 Background: Erlotinib (E,[Tarceva]) is an orally available, reversible inhibitor of the
HER1/EGFR tyrosine kinase that has recently been approved by the FDA for the treatment of …
HER1/EGFR tyrosine kinase that has recently been approved by the FDA for the treatment of …
Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma …
PA Janne, XF Wang, MA Socinski… - Journal of Clinical …, 2010 - ascopubs.org
7503 Background: EGFR kinase inhibitors are effective in never-smokers with NSCLC
especially in those harboring EGFR mutations. In a prior phase III study (TRIBUTE) ECP was …
especially in those harboring EGFR mutations. In a prior phase III study (TRIBUTE) ECP was …
Impact of smoking status in combination treatment with EGFR tyrosine kinase inhibitors and anti-angiogenic agents in advanced non-small cell lung cancer harboring …
Patients with advanced non-small cell lung cancer (NSCLC) who harbor susceptible
epidermal growth factor receptor (EGFR) mutations and are treated with EGFR tyrosine …
epidermal growth factor receptor (EGFR) mutations and are treated with EGFR tyrosine …
[HTML][HTML] Combined inhibitions of glycolysis and AKT/autophagy can overcome resistance to EGFR-targeted therapy of lung cancer
M Ye, S Wang, T Wan, R Jiang, Y Qiu, L Pei… - Journal of …, 2017 - ncbi.nlm.nih.gov
Efficacy of EGFR-targeted tyrosine kinase inhibitors (TKIs), such as erlotinib, to treat human
non-small cell lung cancers (NSCLCs) with activating mutations in EGFR is not persistent …
non-small cell lung cancers (NSCLCs) with activating mutations in EGFR is not persistent …
[HTML][HTML] Meta-analysis of first-line therapies in advanced non–small-cell lung cancer harboring EGFR-activating mutations
Introduction: Tyrosine kinase inhibitors gefitinib, erlotinib, and afatinib have been compared
with chemotherapy as first-line therapies for patients with advanced non–small-cell lung …
with chemotherapy as first-line therapies for patients with advanced non–small-cell lung …
[HTML][HTML] Erlotinib usage after prior treatment with gefitinib in advanced non-small cell lung cancer: A clinical perspective and review of published literature
Erlotinib and gefitinib are among the most widely researched, used and available
molecularly targeted therapies for treatment of advanced non-small cell lung cancer …
molecularly targeted therapies for treatment of advanced non-small cell lung cancer …
Prospective Molecular Marker Analyses of EGFR and KRAS From a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non …
W Brugger, N Triller, M Blasinska-Morawiec… - Journal of Clinical …, 2011 - ascopubs.org
Purpose The phase III, randomized, placebo-controlled Sequential Tarceva in Unresectable
NSCLC (SATURN; BO18192) study found that erlotinib maintenance therapy extended …
NSCLC (SATURN; BO18192) study found that erlotinib maintenance therapy extended …